Hakan Cetin

Therapeutic targeting of the safety factor in myasthenic syndromes 2:44
Therapeutic targeting of the safety factor in myasthenic syndromes
Hakan Cetin • 23 Jun 2021
Research needs in seronegative myasthenia gravis 1:37
Research needs in seronegative myasthenia gravis
Hakan Cetin • 23 Jun 2021
Safety factor at the neuromuscular junction 3:17
Safety factor at the neuromuscular junction
Hakan Cetin • 23 Jun 2021
Reduced safety factor in the pathogenesis of autoimmune and congenital myasthenic syndromes 2:37
Reduced safety factor in the pathogenesis of autoimmune and congenital myasthenic syndromes
Hakan Cetin • 23 Jun 2021
The content of VJNeurology is intended for healthcare professionals